COVID-19 Severity and Waning Immunity After up to 4 mRNA Vaccine Doses in 73  608 Patients With Cancer and 621 475 Matched Controls in Singapore: A Nationwide Cohort Study

CONCLUSION: This cohort study provides evidence of the clinical effectiveness of mRNA-based vaccines against COVID-19 in patients with cancer. Longevity of immunity in preventing severe COVID-19 outcomes in actively treated patients with cancer, cancer survivors, and matched controls was observed at least 5 months after the third or fourth dose.PMID:37440245 | DOI:10.1001/jamaoncol.2023.2271

Source: Cancer Control - July 13, 2023 Category: Cancer & Oncology Authors: Wei Chong Tan Janice Yu Jin Tan Joline Si Jing Lim Ryan Ying Cong Tan Ainsley Ryan Yan Bin Lee Fun Loon Leong Soo Chin Lee Louis Yi Ann Chai Thuan Tong Tan Muhammad Ismail Bin Abdul Malek Benjamin Ong David Chien Lye Calvin J Chiew Wee Joo Chng Soon Thye Source Type: research